Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Alzheimer's Disease

  Free Subscription


Articles published in Brain

Retrieve available abstracts of 202 articles:
HTML format



Single Articles


    July 2021
  1. PAUMIER A, Boisseau S, Jacquier-Sarlin M, Pernet-Gallay K, et al
    Astrocyte-neuron interplay is critical for Alzheimer's disease pathogenesis and is rescued by TRPA1 channel blockade.
    Brain. 2021 Jul 24. pii: 6327685. doi: 10.1093.
    PubMed     Abstract available


  2. GOURMAUD S, Stewart DA, Irwin DJ, Roberts N, et al
    The role of mTORC1 activation in seizure-induced exacerbation of Alzheimer's disease.
    Brain. 2021 Jul 15. pii: 6321945. doi: 10.1093.
    PubMed     Abstract available


  3. BERRON D, van Westen D, Ossenkoppele R, Strandberg O, et al
    Corrigendum to: Medial temporal lobe connectivity and its associations with cognition in early Alzheimer's disease.
    Brain. 2021 Jul 14. pii: 6321152. doi: 10.1093.
    PubMed    


  4. PEREIRA JB, Janelidze S, Smith R, Mattsson-Carlgren N, et al
    Plasma GFAP is an early marker of amyloid-beta but not tau pathology in Alzheimer's disease.
    Brain. 2021 Jul 14. pii: 6321226. doi: 10.1093.
    PubMed     Abstract available


  5. BAILES SM, Lewis LD
    Distinct cardiac-locked brain pulsations in Alzheimer's disease.
    Brain. 2021 Jul 9. pii: 6318392. doi: 10.1093.
    PubMed    


  6. HORIE K, Barthelemy NR, Sato C, Bateman RJ, et al
    Corrigendum to: CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease.
    Brain. 2021 Jul 3. pii: 6313379. doi: 10.1093.
    PubMed    


    June 2021
  7. MATTHEWS DC, Mao X, Dowd K, Tsakanikas D, et al
    Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer's disease.
    Brain. 2021 Jun 18. pii: 6305835. doi: 10.1093.
    PubMed     Abstract available


  8. PATEL AG, Nehete PN, Krivoshik SR, Pei X, et al
    Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer's disease pathology in aged squirrel monkeys.
    Brain. 2021 Jun 15. pii: 6297373. doi: 10.1093.
    PubMed     Abstract available


  9. SCHUMACHER J, Gunter JL, Przybelski SA, Jones DT, et al
    Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks.
    Brain. 2021 Jun 11. pii: 6296589. doi: 10.1093.
    PubMed     Abstract available


    May 2021

  10. Erratum to: The development and convergence of co-pathologies in Alzheimer's disease.
    Brain. 2021 May 23. pii: 6282423. doi: 10.1093.
    PubMed    


  11. DEHGHANI N, Bras J, Guerreiro R
    Erratum to: How understudied populations have contributed to our understanding of Alzheimer's disease genetics.
    Brain. 2021 May 20. pii: 6279241. doi: 10.1093.
    PubMed    


    April 2021
  12. O'CONNOR A, Pannee J, Poole T, Arber C, et al
    Plasma amyloid-beta ratios in autosomal dominant Alzheimer's disease: the influence of genotype.
    Brain. 2021 Apr 23. pii: 6248083. doi: 10.1093.
    PubMed     Abstract available


  13. DEHGHANI N, Bras J, Guerreiro R
    How understudied populations have contributed to our understanding of Alzheimer's disease genetics.
    Brain. 2021 Apr 23. pii: 6247156. doi: 10.1093.
    PubMed     Abstract available


  14. YAO Y, Kang SS, Xia Y, Wang ZH, et al
    A delta-secretase-truncated APP fragment activates CEBPB, mediating Alzheimer's disease pathologies.
    Brain. 2021 Apr 20. pii: 6242262. doi: 10.1093.
    PubMed     Abstract available



  15. Erratum to: Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
    Brain. 2021 Apr 20. pii: 6238673. doi: 10.1093.
    PubMed    


  16. OZAWA S, Hori Y, Shimizu Y, Taniguchi A, et al
    Photo-oxygenation by a biocompatible catalyst reduces amyloid-beta levels in Alzheimer's disease mice.
    Brain. 2021 Apr 14. pii: 6224831. doi: 10.1093.
    PubMed     Abstract available


  17. TOME SO, Thal DR
    Co-pathologies in Alzheimer's disease: just multiple pathologies or partners in crime?
    Brain. 2021;144:706-708.
    PubMed    



  18. Corrigendum to: Monitoring the progression of Alzheimer's disease with tau-PET.
    Brain. 2021 Apr 6. pii: 6213355. doi: 10.1093.
    PubMed    


    March 2021
  19. RAJNA Z, Mattila H, Huotari N, Tuovinen T, et al
    Cardiovascular brain impulses in Alzheimer's disease.
    Brain. 2021 Mar 31. pii: 6206368. doi: 10.1093.
    PubMed     Abstract available


  20. YAP SY, Frias B, Wren MC, Scholl M, et al
    Discriminatory ability of next-generation tau PET tracers for Alzheimer's disease.
    Brain. 2021 Mar 20. pii: 6179104. doi: 10.1093.
    PubMed     Abstract available


  21. EWERS M, Luan Y, Frontzkowski L, Neitzel J, et al
    Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease.
    Brain. 2021 Mar 16. pii: 6174116. doi: 10.1093.
    PubMed     Abstract available


  22. ASBY D, Boche D, Allan S, Love S, et al
    Systemic infection exacerbates cerebrovascular dysfunction in Alzheimer's disease.
    Brain. 2021 Mar 16. pii: 6173392. doi: 10.1093.
    PubMed     Abstract available


  23. SPINA S, La Joie R, Petersen C, Nolan AL, et al
    Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease.
    Brain. 2021 Mar 9. pii: 6164966. doi: 10.1093.
    PubMed     Abstract available


  24. HUSAIN M
    Blood tests to screen for Alzheimer's disease.
    Brain. 2021;144:355-356.
    PubMed    


  25. KIM JH, Afridi R, Han J, Jung HG, et al
    Gamma subunit of complement component 8 is a neuroinflammation inhibitor.
    Brain. 2021;144:528-552.
    PubMed     Abstract available


    February 2021
  26. JAGUST W
    Integrating events in the disintegration of Alzheimer's disease.
    Brain. 2021;144:11-14.
    PubMed    


  27. TIJMS BM, Teunissen CE
    Concatenating plasma p-tau to Alzheimer's disease.
    Brain. 2021;144:14-17.
    PubMed    


    January 2021
  28. KESHAVAN A, Pannee J, Karikari TK, Rodriguez JL, et al
    Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70.
    Brain. 2021 Jan 22. pii: 6105867. doi: 10.1093.
    PubMed     Abstract available



  29. Erratum to: Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons.
    Brain. 2021 Jan 12. pii: 6091150. doi: 10.1093.
    PubMed    


    December 2020
  30. JOHNSON JCS, Marshall CR, Weil RS, Bamiou DE, et al
    Hearing and dementia: from ears to brain.
    Brain. 2020 Dec 22. pii: 6044086. doi: 10.1093.
    PubMed     Abstract available


  31. MONTERO-CRESPO M, Dominguez-Alvaro M, Alonso-Nanclares L, DeFelipe J, et al
    Three-dimensional analysis of synaptic organization in the hippocampal CA1 field in Alzheimer's disease.
    Brain. 2020 Dec 16. pii: 6038920. doi: 10.1093.
    PubMed     Abstract available


  32. HORIE K, Barthelemy NR, Sato C, Bateman RJ, et al
    CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease.
    Brain. 2020 Dec 7. pii: 6024973. doi: 10.1093.
    PubMed     Abstract available


  33. TEUNISSEN CE, Thijssen EH, Verberk IMW
    Plasma p-tau217: from 'new kid' to most promising candidate for Alzheimer's disease blood test.
    Brain. 2020;143:3170-3172.
    PubMed    


  34. PEREIRA JB, Janelidze S, Ossenkoppele R, Kvartsberg H, et al
    Untangling the association of amyloid-beta and tau with synaptic and axonal loss in Alzheimer's disease.
    Brain. 2020 Dec 5. pii: 6024803. doi: 10.1093.
    PubMed     Abstract available


  35. TIJMS BM, Gobom J, Reus L, Jansen I, et al
    Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics.
    Brain. 2020;143:3776-3792.
    PubMed     Abstract available


  36. SMITH R, Strandberg O, Mattsson-Carlgren N, Leuzy A, et al
    The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
    Brain. 2020;143:3805-3815.
    PubMed     Abstract available


  37. FLORES-AGUILAR L, Iulita MF, Kovecses O, Torres MD, et al
    Evolution of neuroinflammation across the lifespan of individuals with Down syndrome.
    Brain. 2020;143:3653-3671.
    PubMed     Abstract available


    November 2020
  38. MOSCOSO A, Grothe MJ, Ashton NJ, Karikari TK, et al
    Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
    Brain. 2020 Nov 30. pii: 6012955. doi: 10.1093.
    PubMed     Abstract available


  39. BRIER MR, Day GS
    Serum neurofilament light chain uncovers neurodegeneration early in the course of Alzheimer's disease.
    Brain. 2020 Nov 30. pii: 6012788. doi: 10.1093.
    PubMed    


  40. SUR C, Kost J, Scott D, Adamczuk K, et al
    BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
    Brain. 2020 Nov 30. pii: 6012787. doi: 10.1093.
    PubMed     Abstract available


  41. RUAN Z, Pathak D, Venkatesan Kalavai S, Yoshii-Kitahara A, et al
    Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons.
    Brain. 2020 Nov 27. pii: 6007752. doi: 10.1093.
    PubMed     Abstract available


  42. BENEDET AL, Leuzy A, Pascoal TA, Ashton NJ, et al
    Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Brain. 2020 Nov 19. pii: 5990278. doi: 10.1093.
    PubMed     Abstract available


  43. JIA L, Li F, Wei C, Zhu M, et al
    Prediction of Alzheimer's disease using multi-variants from a Chinese genome-wide association study.
    Brain. 2020 Nov 14. pii: 5981992. doi: 10.1093.
    PubMed     Abstract available


  44. LIU KY, Reeves S, McAleese KE, Attems J, et al
    Neuropsychiatric symptoms in limbic-predominant age-related TDP-43 encephalopathy and Alzheimer's disease.
    Brain. 2020 Nov 14. pii: 5981742. doi: 10.1093.
    PubMed     Abstract available


  45. JI X, Liu G
    rs34331204 regulates TSPAN13 expression and contributes to Alzheimer's disease with sex differences.
    Brain. 2020 Nov 11. pii: 5974904. doi: 10.1093.
    PubMed    


  46. DUMITRESCU L, Hohman TJ
    Reply: rs34331204 regulates TSPAN13 expression and contributes to Alzheimer's disease with sex differences.
    Brain. 2020 Nov 11. pii: 5974883. doi: 10.1093.
    PubMed    


  47. JOSEPHS KA, Martin PR, Weigand SD, Tosakulwong N, et al
    Protein contributions to brain atrophy acceleration in Alzheimer's disease and primary age-related tauopathy.
    Brain. 2020 Nov 5. pii: 5956321. doi: 10.1093.
    PubMed     Abstract available


  48. SOLEIMANI-MEIGOONI DN, Iaccarino L, La Joie R, Baker S, et al
    18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.
    Brain. 2020 Nov 3. pii: 5952719. doi: 10.1093.
    PubMed     Abstract available


    October 2020
  49. MATTSSON-CARLGREN N, Janelidze S, Palmqvist S, Cullen N, et al
    Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease.
    Brain. 2020 Oct 17. pii: 5929275. doi: 10.1093.
    PubMed     Abstract available


    September 2020
  50. FORSBERG MOREN A, Varrone A
    Timing is everything: tau imaging across stages of Alzheimer's disease.
    Brain. 2020;143:2634-2636.
    PubMed    


  51. HARDY CJD, Yong KXX, Goll JC, Crutch SJ, et al
    Impairments of auditory scene analysis in posterior cortical atrophy.
    Brain. 2020 Sep 1. pii: 5900355. doi: 10.1093.
    PubMed     Abstract available


    August 2020
  52. HORSAGER J, Andersen KB, Knudsen K, Skjaerbaek C, et al
    Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study.
    Brain. 2020 Aug 24. pii: 5896254. doi: 10.1093.
    PubMed     Abstract available


  53. DRUMMOND E, Pires G, MacMurray C, Askenazi M, et al
    Phosphorylated tau interactome in the human Alzheimer's disease brain.
    Brain. 2020 Aug 19. pii: 5893817. doi: 10.1093.
    PubMed     Abstract available


  54. DUMITRESCU L, Mahoney ER, Mukherjee S, Lee ML, et al
    Genetic variants and functional pathways associated with resilience to Alzheimer's disease.
    Brain. 2020;143:2561-2575.
    PubMed     Abstract available


    July 2020
  55. HARRISON IF, Ismail O, Machhada A, Colgan N, et al
    Impaired glymphatic function and clearance of tau in an Alzheimer's disease model.
    Brain. 2020 Jul 23. pii: 5875735. doi: 10.1093.
    PubMed     Abstract available


  56. PASCOAL TA, Therriault J, Benedet AL, Savard M, et al
    18F-MK-6240 PET for early and late detection of neurofibrillary tangles.
    Brain. 2020 Jul 16. pii: 5872095. doi: 10.1093.
    PubMed     Abstract available


  57. COUSINS KAQ, Irwin DJ, Wolk DA, Lee EB, et al
    ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration.
    Brain. 2020;143:2295-2311.
    PubMed     Abstract available


    June 2020
  58. FAN CC, Banks SJ, Thompson WK, Chen CH, et al
    Sex-dependent autosomal effects on clinical progression of Alzheimer's disease.
    Brain. 2020 Jun 27. pii: 5863662. doi: 10.1093.
    PubMed     Abstract available


  59. SINTINI I, Graff-Radford J, Senjem ML, Schwarz CG, et al
    Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes.
    Brain. 2020 Jun 23. pii: 5861030. doi: 10.1093.
    PubMed     Abstract available


  60. PRZYBYLA M, van Eersel J, van Hummel A, van der Hoven J, et al
    Onset of hippocampal network aberration and memory deficits in P301S tau mice are associated with an early gene signature.
    Brain. 2020;143:1889-1904.
    PubMed     Abstract available


    May 2020
  61. ARENA JD, Smith DH, Lee EB, Gibbons GS, et al
    Tau immunophenotypes in chronic traumatic encephalopathy recapitulate those of ageing and Alzheimer's disease.
    Brain. 2020 May 11. pii: 5835545. doi: 10.1093.
    PubMed     Abstract available


  62. MALPETTI M, Kievit RA, Passamonti L, Jones PS, et al
    Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.
    Brain. 2020 May 7. pii: 5831943. doi: 10.1093.
    PubMed     Abstract available


  63. QIU S, Joshi PS, Miller MI, Xue C, et al
    Development and validation of an interpretable deep learning framework for Alzheimer's disease classification.
    Brain. 2020 May 1. pii: 5827821. doi: 10.1093.
    PubMed     Abstract available


    April 2020
  64. SPOTORNO N, Acosta-Cabronero J, Stomrud E, Lampinen B, et al
    Relationship between cortical iron and tau aggregation in Alzheimer's disease.
    Brain. 2020 Apr 24. pii: 5824902. doi: 10.1093.
    PubMed     Abstract available


  65. BERRON D, van Westen D, Ossenkoppele R, Strandberg O, et al
    Medial temporal lobe connectivity and its associations with cognition in early Alzheimer's disease.
    Brain. 2020 Apr 6. pii: 5816707. doi: 10.1093.
    PubMed     Abstract available


  66. VELDSMAN M
    Atrophy network mapping of transdiagnostic cognitive and neuropsychiatric symptoms.
    Brain. 2020;143:1053-1056.
    PubMed    


  67. DE WOLF F, Ghanbari M, Licher S, McRae-McKee K, et al
    Plasma tau, neurofilament light chain and amyloid-beta levels and risk of dementia; a population-based cohort study.
    Brain. 2020;143:1220-1232.
    PubMed     Abstract available


    March 2020
  68. TETREAULT AM, Phan T, Orlando D, Lyu I, et al
    Network localization of clinical, cognitive, and neuropsychiatric symptoms in Alzheimer's disease.
    Brain. 2020 Mar 16. pii: 5807900. doi: 10.1093.
    PubMed     Abstract available


  69. FERNANDEZ-CABELLO S, Kronbichler M, Van Dijk KRA, Goodman JA, et al
    Basal forebrain volume reliably predicts the cortical spread of Alzheimer's degeneration.
    Brain. 2020;143:993-1009.
    PubMed     Abstract available


  70. AGOSTA F, Canu E, Filippi M
    Virtual reality and real-time neurofeedback functional MRI: a breakthrough in foreseeing Alzheimer's disease?
    Brain. 2020;143:722-726.
    PubMed    


  71. SKOURAS S, Torner J, Andersson P, Koush Y, et al
    Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation.
    Brain. 2020;143:976-992.
    PubMed     Abstract available


    February 2020
  72. NELSON PT
    Reply: Selected cryptic exons accumulate in hippocampal cell nuclei in Alzheimer's disease with and without associated TDP-43 proteinopathy.
    Brain. 2020 Feb 4. pii: 5722221. doi: 10.1093.
    PubMed    


  73. TORRES P, Andres-Benito P, Fernandez-Bernal A, Ricart M, et al
    Selected cryptic exons accumulate in hippocampal cell nuclei in Alzheimer's disease with and without associated TDP-43 proteinopathy.
    Brain. 2020 Feb 4. pii: 5722222. doi: 10.1093.
    PubMed    


  74. PICHET BINETTE A, Gonneaud J, Vogel JW, La Joie R, et al
    Morphometric network differences in ageing versus Alzheimer's disease dementia.
    Brain. 2020;143:635-649.
    PubMed     Abstract available


  75. ITURRIA-MEDINA Y, Khan AF, Adewale Q, Shirazi AH, et al
    Blood and brain gene expression trajectories mirror neuropathology and clinical deterioration in neurodegeneration.
    Brain. 2020;143:661-673.
    PubMed     Abstract available


  76. TEYLAN M, Mock C, Gauthreaux K, Chen YC, et al
    Cognitive trajectory in mild cognitive impairment due to primary age-related tauopathy.
    Brain. 2020;143:611-621.
    PubMed     Abstract available


    January 2020
  77. ROBINSON JL, Richardson H, Xie SX, Suh E, et al
    The development and convergence of co-pathologies in Alzheimer's disease.
    Brain. 2020 Jan 15. pii: 6101614. doi: 10.1093.
    PubMed     Abstract available


  78. BETTHAUSER TJ, Koscik RL, Jonaitis EM, Allison SL, et al
    Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
    Brain. 2020;143:320-335.
    PubMed     Abstract available


  79. ROWE J
    Editorial.
    Brain. 2020;143:1.
    PubMed    


    December 2019
  80. BADHWAR A, McFall GP, Sapkota S, Black SE, et al
    A multiomics approach to heterogeneity in Alzheimer's disease: focused review and roadmap.
    Brain. 2019 Dec 31. pii: 5692271. doi: 10.1093.
    PubMed     Abstract available


  81. GOURMAUD S, Shou H, Irwin DJ, Sansalone K, et al
    Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy.
    Brain. 2019 Dec 13. pii: 5675543. doi: 10.1093.
    PubMed     Abstract available


  82. BLENNOW K, Chen C, Cicognola C, Wildsmith KR, et al
    Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology.
    Brain. 2019 Dec 13. pii: 5675540. doi: 10.1093.
    PubMed     Abstract available


  83. KORONYO-HAMAOUI M, Sheyn J, Hayden EY, Li S, et al
    Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease.
    Brain. 2019 Dec 3. pii: 5651064. doi: 10.1093.
    PubMed     Abstract available


    November 2019
  84. MORRONE CD, Bazzigaluppi P, Beckett TL, Hill ME, et al
    Regional differences in Alzheimer's disease pathology confound behavioural rescue after amyloid-beta attenuation.
    Brain. 2019 Nov 28. pii: 5647334. doi: 10.1093.
    PubMed     Abstract available


  85. YOUNAN D, Petkus AJ, Widaman KF, Wang X, et al
    Particulate matter and episodic memory decline mediated by early neuroanatomic biomarkers of Alzheimer's disease.
    Brain. 2019 Nov 20. pii: 5628036. doi: 10.1093.
    PubMed     Abstract available


    October 2019
  86. LIU G, Zhang H, Liu B, Ji X, et al
    Rs2293871 regulates HTRA1 expression and affects cerebral small vessel stroke and Alzheimer's disease.
    Brain. 2019 Oct 11. pii: 5585665. doi: 10.1093.
    PubMed    


  87. ZHANG M, Dilliott AA, Khallaf R, Robinson JF, et al
    Genetic and epigenetic study of an Alzheimer's disease family with monozygotic triplets.
    Brain. 2019 Oct 3. pii: 5580538. doi: 10.1093.
    PubMed     Abstract available


    September 2019
  88. TAKAHATA K, Kimura Y, Sahara N, Koga S, et al
    PET-detectable tau pathology correlates with long-term neuropsychiatric outcomes in patients with traumatic brain injury.
    Brain. 2019 Sep 2. pii: 5556830. doi: 10.1093.
    PubMed     Abstract available


  89. DUMITRESCU L, Barnes LL, Thambisetty M, Beecham G, et al
    Sex differences in the genetic predictors of Alzheimer's pathology.
    Brain. 2019;142:2581-2589.
    PubMed     Abstract available


    August 2019
  90. PANZA F, Lozupone M, Solfrizzi V, Watling M, et al
    Time to test antibacterial therapy in Alzheimer's disease.
    Brain. 2019 Aug 29. pii: 5556366. doi: 10.1093.
    PubMed     Abstract available


    July 2019
  91. OVERK C, Masliah E
    Could changing the course of Alzheimer's disease pathology with immunotherapy prevent dementia?
    Brain. 2019;142:1853-1855.
    PubMed    


    June 2019
  92. GAUBERT S, Raimondo F, Houot M, Corsi MC, et al
    EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease.
    Brain. 2019 Jun 18. pii: 5519996. doi: 10.1093.
    PubMed     Abstract available


  93. MAASS A, Berron D, Harrison TM, Adams JN, et al
    Alzheimer's pathology targets distinct memory networks in the ageing brain.
    Brain. 2019 Jun 14. pii: 5519092. doi: 10.1093.
    PubMed     Abstract available


  94. NICOLL JAR, Buckland GR, Harrison CH, Page A, et al
    Persistent neuropathological effects 14 years following amyloid-beta immunization in Alzheimer's disease.
    Brain. 2019 Jun 3. pii: 5510133. doi: 10.1093.
    PubMed     Abstract available


  95. PHILLIPS JS, Da Re F, Irwin DJ, McMillan CT, et al
    Longitudinal progression of grey matter atrophy in non-amnestic Alzheimer's disease.
    Brain. 2019;142:1701-1722.
    PubMed     Abstract available


  96. JEGANATHAN J, Breakspear M
    Are the 'atoms of thought' longer in Lewy body dementia?
    Brain. 2019;142:1494-1497.
    PubMed    


  97. HOWETT D, Castegnaro A, Krzywicka K, Hagman J, et al
    Differentiation of mild cognitive impairment using an entorhinal cortex-based test of virtual reality navigation.
    Brain. 2019;142:1751-1766.
    PubMed     Abstract available


  98. NELSON PT, Dickson DW, Trojanowski JQ, Jack CR, et al
    Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report.
    Brain. 2019;142:1503-1527.
    PubMed     Abstract available


  99. ALBERT M, Mairet-Coello G, Danis C, Lieger S, et al
    Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody.
    Brain. 2019;142:1736-1750.
    PubMed     Abstract available


  100. SCHUMACHER J, Peraza LR, Firbank M, Thomas AJ, et al
    Dysfunctional brain dynamics and their origin in Lewy body dementia.
    Brain. 2019;142:1767-1782.
    PubMed     Abstract available


    May 2019
  101. BRINKMALM G, Hong W, Wang Z, Liu W, et al
    Identification of neurotoxic cross-linked amyloid-beta dimers in the Alzheimer's brain.
    Brain. 2019;142:1441-1457.
    PubMed     Abstract available


  102. BATEMAN RJ, Mawuenyega KG, Wildburger NC
    The structure of amyloid-beta dimers in Alzheimer's disease brain: a step forward for oligomers.
    Brain. 2019;142:1168-1169.
    PubMed    


    April 2019
  103. PONTECORVO MJ, Devous MD, Kennedy I, Navitsky M, et al
    A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
    Brain. 2019 Apr 22. pii: 5476105. doi: 10.1093.
    PubMed     Abstract available


  104. LYON L
    Is an epidemic of sleeplessness increasing the incidence of Alzheimer's disease?
    Brain. 2019 Apr 1. pii: 5425265. doi: 10.1093.
    PubMed    


  105. ILLAN-GALA I, Montal V, Borrego-Ecija S, Vilaplana E, et al
    Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy.
    Brain. 2019;142:1121-1133.
    PubMed     Abstract available


  106. KNOPMAN DS, Lundt ES, Therneau TM, Vemuri P, et al
    Entorhinal cortex tau, amyloid-beta, cortical thickness and memory performance in non-demented subjects.
    Brain. 2019;142:1148-1160.
    PubMed     Abstract available


    March 2019
  107. VOGLEIN J, Paumier K, Jucker M, Preische O, et al
    Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease.
    Brain. 2019 Mar 20. pii: 5416202. doi: 10.1093.
    PubMed     Abstract available


  108. ARENAZA-URQUIJO EM, Przybelski SA, Lesnick TL, Graff-Radford J, et al
    The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies.
    Brain. 2019 Mar 8. pii: 5372751. doi: 10.1093.
    PubMed     Abstract available


    February 2019
  109. YAMAZAKI Y, Shinohara M, Shinohara M, Yamazaki A, et al
    Selective loss of cortical endothelial tight junction proteins during Alzheimer's disease progression.
    Brain. 2019 Feb 15. pii: 5321132. doi: 10.1093.
    PubMed     Abstract available


  110. FRANZMEIER N, Rubinski A, Neitzel J, Kim Y, et al
    Functional connectivity associated with tau levels in ageing, Alzheimer's, and small vessel disease.
    Brain. 2019 Feb 15. pii: 5321130. doi: 10.1093.
    PubMed     Abstract available


  111. GORDON BA, Blazey TM, Christensen J, Dincer A, et al
    Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
    Brain. 2019 Feb 11. pii: 5315649. doi: 10.1093.
    PubMed     Abstract available


  112. TAN CH, Bonham LW, Fan CC, Mormino EC, et al
    Polygenic hazard score, amyloid deposition and Alzheimer's neurodegeneration.
    Brain. 2019;142:460-470.
    PubMed     Abstract available


  113. KULLMANN DM
    Editorial.
    Brain. 2019;142:227.
    PubMed    


    January 2019
  114. ZHENG Y, Liu A, Wang ZJ, Cao Q, et al
    Inhibition of EHMT1/2 rescues synaptic and cognitive functions for Alzheimer's disease.
    Brain. 2019 Jan 22. pii: 5298257. doi: 10.1093.
    PubMed     Abstract available


  115. PARK JC, Han SH, Yi D, Byun MS, et al
    Plasma tau/amyloid-beta1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease.
    Brain. 2019 Jan 21. pii: 5292577. doi: 10.1093.
    PubMed     Abstract available


  116. ZHU BL, Long Y, Luo W, Yan Z, et al
    MMP13 inhibition rescues cognitive decline in Alzheimer transgenic mice via BACE1 regulation.
    Brain. 2019;142:176-192.
    PubMed     Abstract available


  117. POWER MC
    Growing evidence links air pollution exposure to risk of Alzheimer's disease and related dementia.
    Brain. 2019;143:8-10.
    PubMed    


    December 2018
  118. DARBY RR, Joutsa J, Fox MD
    Network localization of heterogeneous neuroimaging findings.
    Brain. 2018 Dec 14. pii: 5244188. doi: 10.1093.
    PubMed     Abstract available


  119. KOLANKO MA, Malhotra PA
    Exploring Alzheimer's disease subtypes at the prodromal stage.
    Brain. 2018;141:3285-3287.
    PubMed    


    October 2018
  120. TEN KATE M, Dicks E, Visser PJ, van der Flier WM, et al
    Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline.
    Brain. 2018 Oct 22. pii: 5142624. doi: 10.1093.
    PubMed     Abstract available


  121. JACOBS HIL, Buckley RF
    Where do white matter alterations dovetail with the cascade model of Alzheimer's disease?
    Brain. 2018;141:2830-2833.
    PubMed    


    September 2018
  122. ARAQUE CABALLERO MA, Suarez-Calvet M, Duering M, Franzmeier N, et al
    White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease.
    Brain. 2018 Sep 19. pii: 5104289. doi: 10.1093.
    PubMed     Abstract available


    August 2018
  123. PETYUK VA, Chang R, Ramirez-Restrepo M, Beckmann ND, et al
    The human brainome: network analysis identifies HSPA2 as a novel Alzheimer's disease target.
    Brain. 2018 Aug 20. pii: 5077110. doi: 10.1093.
    PubMed     Abstract available


  124. GAO S, Casey AE, Sargeant TJ, Makinen VP, et al
    Genetic variation within endolysosomal system is associated with late-onset Alzheimer's disease.
    Brain. 2018 Aug 16. pii: 5075310. doi: 10.1093.
    PubMed     Abstract available


  125. GAUTHIER S, Herrmann N, Rosa-Neto P
    Optimal use of cholinergic drugs in Alzheimer's disease.
    Brain. 2018 Aug 2. pii: 5064194. doi: 10.1093.
    PubMed    


  126. HAMPEL H, Cavedo E, Vergallo A
    Reply: Optimal use of cholinergic drugs in Alzheimer's disease.
    Brain. 2018 Aug 2. pii: 5064191. doi: 10.1093.
    PubMed    


  127. SAMI S, Williams N, Hughes LE, Cope TE, et al
    Neurophysiological signatures of Alzheimer's disease and frontotemporal lobar degeneration: pathology versus phenotype.
    Brain. 2018;141:2500-2510.
    PubMed     Abstract available


    July 2018
  128. DANI M, Wood M, Mizoguchi R, Fan Z, et al
    Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.
    Brain. 2018 Jul 20. pii: 5056962. doi: 10.1093.
    PubMed     Abstract available


  129. GROTHE MJ, Sepulcre J, Gonzalez-Escamilla G, Jelistratova I, et al
    Molecular properties underlying regional vulnerability to Alzheimer's disease pathology.
    Brain. 2018 Jul 16. pii: 5054650. doi: 10.1093.
    PubMed     Abstract available


    June 2018
  130. COSTA C, Romoli M, Calabresi P
    Late onset epilepsy and Alzheimer's disease: exploring the dual pathogenic role of amyloid-beta.
    Brain. 2018 Jun 9. pii: 5035368. doi: 10.1093.
    PubMed    


  131. SEN A, Husain M
    Reply: Late onset epilepsy and Alzheimer's disease: exploring the dual pathogenic role of amyloid-beta.
    Brain. 2018 Jun 9. pii: 5035367. doi: 10.1093.
    PubMed    


  132. TIJMS BM, Visser PJ
    Chasing the start of sporadic Alzheimer's disease running in families.
    Brain. 2018;141:1589-1591.
    PubMed    


    May 2018
  133. SCELSI MA, Khan RR, Lorenzi M, Christopher L, et al
    Genetic study of multimodal imaging Alzheimer's disease progression score implicates novel loci.
    Brain. 2018 May 30. pii: 5025682. doi: 10.1093.
    PubMed     Abstract available


  134. HAMPEL H, Mesulam MM, Cuello AC, Farlow MR, et al
    The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.
    Brain. 2018 May 29. pii: 5023826. doi: 10.1093.
    PubMed     Abstract available


  135. LI D, Donohue MC
    Disease progression models for dominantly-inherited Alzheimer's disease.
    Brain. 2018;141:1244-1246.
    PubMed    


  136. HANSSON O, Mormino EC
    Is longitudinal tau PET ready for use in Alzheimer's disease clinical trials?
    Brain. 2018;141:1241-1244.
    PubMed    


    April 2018
  137. VOGEL JW, Vachon-Presseau E, Pichet Binette A, Tam A, et al
    Brain properties predict proximity to symptom onset in sporadic Alzheimer's disease.
    Brain. 2018 Apr 23. pii: 4969934. doi: 10.1093.
    PubMed     Abstract available


  138. SABRI O, Meyer PM, Graf S, Hesse S, et al
    Cognitive correlates of alpha4beta2 nicotinic acetylcholine receptors in mild Alzheimer's dementia.
    Brain. 2018 Apr 17. pii: 4974320. doi: 10.1093.
    PubMed     Abstract available


  139. MISHRA S, Blazey TM, Holtzman DM, Cruchaga C, et al
    Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE varepsilon4 genotype.
    Brain. 2018 Apr 17. pii: 4974818. doi: 10.1093.
    PubMed     Abstract available


  140. MCALEESE KE, Walker L, Colloby SJ, Taylor JP, et al
    Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease?
    Brain. 2018 Apr 13. pii: 4969931. doi: 10.1093.
    PubMed    


  141. MITO R, Raffelt D, Dhollander T, Vaughan DN, et al
    Reply: Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease?
    Brain. 2018 Apr 13. pii: 4969932. doi: 10.1093.
    PubMed    


    March 2018
  142. HAMELIN L, Lagarde J, Dorothee G, Potier MC, et al
    Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease.
    Brain. 2018 Mar 28. pii: 4955843. doi: 10.1093.
    PubMed     Abstract available


  143. OXTOBY NP, Young AL, Cash DM, Benzinger TLS, et al
    Data-driven models of dominantly-inherited Alzheimer's disease progression.
    Brain. 2018 Mar 22. pii: 4951528. doi: 10.1093.
    PubMed     Abstract available


  144. JACK CR JR, Wiste HJ, Schwarz CG, Lowe VJ, et al
    Longitudinal tau PET in ageing and Alzheimer's disease.
    Brain. 2018 Mar 12. pii: 4929907. doi: 10.1093.
    PubMed     Abstract available


  145. CHHATWAL JP, Schultz AP, Johnson KA, Hedden T, et al
    Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing.
    Brain. 2018 Mar 7. pii: 4924520. doi: 10.1093.
    PubMed     Abstract available


  146. NAKAMURA A, Cuesta P, Fernandez A, Arahata Y, et al
    Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease.
    Brain. 2018 Mar 7. pii: 4924218. doi: 10.1093.
    PubMed     Abstract available


  147. SULTZER DL
    Cognitive ageing and Alzheimer's disease: the cholinergic system redux.
    Brain. 2018;141:626-628.
    PubMed    


    February 2018
  148. FRANZMEIER N, Duzel E, Jessen F, Buerger K, et al
    Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease.
    Brain. 2018 Feb 15. pii: 4862492. doi: 10.1093.
    PubMed     Abstract available


  149. WHITWELL JL
    Multimodal neuroimaging provides insights into the biology of Alzheimer's disease.
    Brain. 2018;141:326-329.
    PubMed    


    January 2018
  150. HOENIG MC, Bischof GN, Seemiller J, Hammes J, et al
    Networks of tau distribution in Alzheimer's disease.
    Brain. 2018 Jan 5. pii: 4791255. doi: 10.1093.
    PubMed     Abstract available


  151. RICHTER N, Beckers N, Onur OA, Dietlein M, et al
    Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer's disease.
    Brain. 2018 Jan 4. pii: 4788772. doi: 10.1093.
    PubMed     Abstract available


  152. MITO R, Raffelt D, Dhollander T, Vaughan DN, et al
    Fibre-specific white matter reductions in Alzheimer's disease and mild cognitive impairment.
    Brain. 2018 Jan 4. pii: 4788771. doi: 10.1093.
    PubMed     Abstract available


  153. HERHOLZ K
    Spread of tau deposits: can we trust in vivo findings?
    Brain. 2018;141:10-12.
    PubMed    


  154. GRATWICKE JP, Foltynie T
    Early nucleus basalis of Meynert degeneration predicts cognitive decline in Parkinson's disease.
    Brain. 2018;141:7-10.
    PubMed    


    December 2017
  155. COPE TE, Rittman T, Borchert RJ, Jones PS, et al
    Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy.
    Brain. 2017 Dec 26. pii: 4775021. doi: 10.1093.
    PubMed    


  156. MAEZAWA I, Nguyen HM, Di Lucente J, Jenkins DP, et al
    Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept.
    Brain. 2017 Dec 18. pii: 4759461. doi: 10.1093.
    PubMed     Abstract available


  157. LOWE VJ, Wiste HJ, Senjem ML, Weigand SD, et al
    Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.
    Brain. 2017 Dec 8. pii: 4712020. doi: 10.1093.
    PubMed     Abstract available


  158. FRANZMEIER N, Dyrba M
    Functional brain network architecture may route progression of Alzheimer's disease pathology.
    Brain. 2017;140:3077-3080.
    PubMed    


  159. MUTLU J, Landeau B, Gaubert M, de La Sayette V, et al
    Distinct influence of specific versus global connectivity on the different Alzheimer's disease biomarkers.
    Brain. 2017;140:3317-3328.
    PubMed    


  160. COLOM-CADENA M, Pegueroles J, Herrmann AG, Henstridge CM, et al
    Synaptic phosphorylated alpha-synuclein in dementia with Lewy bodies.
    Brain. 2017;140:3204-3214.
    PubMed     Abstract available


  161. SANTAMARIA-GARCIA H, Baez S, Reyes P, Santamaria-Garcia JA, et al
    A lesion model of envy and Schadenfreude: legal, deservingness and moral dimensions as revealed by neurodegeneration.
    Brain. 2017;140:3357-3377.
    PubMed     Abstract available


  162. PERRY DC, Brown JA, Possin KL, Datta S, et al
    Clinicopathological correlations in behavioural variant frontotemporal dementia.
    Brain. 2017;140:3329-3345.
    PubMed     Abstract available


  163. RODRIGUEZ-RODRIGUEZ P, Sandebring-Matton A, Merino-Serrais P, Parrado-Fernandez C, et al
    Tau hyperphosphorylation induces oligomeric insulin accumulation and insulin resistance in neurons.
    Brain. 2017;140:3269-3285.
    PubMed     Abstract available


    November 2017
  164. SHINOHARA M, Koga S, Konno T, Nix J, et al
    Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-beta42 in Alzheimer's disease.
    Brain. 2017 Nov 17. doi: 10.1093.
    PubMed     Abstract available


  165. BUSTOS FJ, Ampuero E, Jury N, Aguilar R, et al
    Epigenetic editing of the Dlg4/PSD95 gene improves cognition in aged and Alzheimer's disease mice.
    Brain. 2017 Nov 16. doi: 10.1093.
    PubMed     Abstract available


  166. GRINBERG LT, Heinsen H
    Light at the beginning of the tunnel? Investigating early mechanistic changes in Alzheimer's disease.
    Brain. 2017;140:2770-2773.
    PubMed    


    October 2017
  167. DU F, Yu Q, Yan S, Hu G, et al
    PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer's disease.
    Brain. 2017 Oct 25. doi: 10.1093.
    PubMed     Abstract available


  168. BEJANIN A, Schonhaut DR, La Joie R, Kramer JH, et al
    Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Brain. 2017 Oct 7. doi: 10.1093.
    PubMed     Abstract available


    September 2017
  169. RORABAUGH JM, Chalermpalanupap T, Botz-Zapp CA, Fu VM, et al
    Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer's disease.
    Brain. 2017 Sep 25. doi: 10.1093.
    PubMed     Abstract available


  170. CHONG JSX, Liu S, Loke YM, Hilal S, et al
    Influence of cerebrovascular disease on brain networks in prodromal and clinical Alzheimer's disease.
    Brain. 2017 Sep 19. doi: 10.1093.
    PubMed     Abstract available


  171. SCHOLL M, Ossenkoppele R, Strandberg O, Palmqvist S, et al
    Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease.
    Brain. 2017;140:2286-2294.
    PubMed     Abstract available


    August 2017
  172. DERRY PJ, Kent TA
    Correlating quantitative susceptibility mapping with cognitive decline in Alzheimer's disease.
    Brain. 2017;140:2069-2072.
    PubMed    


  173. KIM H, Yoo J, Shin J, Chang Y, et al
    Modelling APOE varepsilon3/4 allele-associated sporadic Alzheimer's disease in an induced neuron.
    Brain. 2017;140:2193-2209.
    PubMed     Abstract available


  174. AYTON S, Fazlollahi A, Bourgeat P, Raniga P, et al
    Cerebral quantitative susceptibility mapping predicts amyloid-beta-related cognitive decline.
    Brain. 2017;140:2112-2119.
    PubMed     Abstract available


    July 2017
  175. JACOBS HIL, Hopkins DA, Mayrhofer HC, Bruner E, et al
    The cerebellum in Alzheimer's disease: evaluating its role in cognitive decline.
    Brain. 2017 Jul 28. doi: 10.1093.
    PubMed     Abstract available


  176. YEW B, Nation DA
    Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
    Brain. 2017;140:1987-2001.
    PubMed     Abstract available


  177. MARKUS HS
    Cerebrovascular abnormalities in Alzheimer's dementia: a more tractable treatment target?
    Brain. 2017;140:1822-1825.
    PubMed    


  178. KREISL WC
    Discerning the relationship between microglial activation and Alzheimer's disease.
    Brain. 2017;140:1825-1828.
    PubMed    


    June 2017
  179. GEORGE C, Gontier G, Lacube P, Francois JC, et al
    The Alzheimer's disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons.
    Brain. 2017 Jun 8. doi: 10.1093.
    PubMed     Abstract available


    May 2017
  180. PARBO P, Ismail R, Hansen KV, Amidi A, et al
    Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease.
    Brain. 2017 May 28. doi: 10.1093.
    PubMed     Abstract available


  181. DANSOKHO C, Aucouturier P, Dorothee G
    Beneficial effect of interleukin-2-based immunomodulation in Alzheimer-like pathology.
    Brain. 2017 May 12. doi: 10.1093.
    PubMed    


  182. ALVES S, Churlaud G, Klatzmann D, Cartier N, et al
    Reply: Beneficial effect of interleukin-2-based immunomodulation in Alzheimer-like pathology.
    Brain. 2017 May 12. doi: 10.1093.
    PubMed    


  183. TOSUN D, Landau S, Aisen PS, Petersen RC, et al
    Association between tau deposition and antecedent amyloid-beta accumulation rates in normal and early symptomatic individuals.
    Brain. 2017;140:1499-1512.
    PubMed     Abstract available


    April 2017
  184. HARDY J, De Strooper B
    Alzheimer's disease: where next for anti-amyloid therapies?
    Brain. 2017;140:853-855.
    PubMed    


  185. CARAVAGGIO F, Graff-Guerrero A
    Is antipsychotic sensitivity in Alzheimer's disease secondary to abnormal blood-brain barrier integrity?
    Brain. 2017;140:865-867.
    PubMed    


    March 2017
  186. YU M, Engels MM, Hillebrand A, van Straaten EC, et al
    Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study.
    Brain. 2017 Mar 16. doi: 10.1093.
    PubMed     Abstract available


  187. ROBERTS BR, Lind M, Wagen AZ, Rembach A, et al
    Biochemically-defined pools of amyloid-beta in sporadic Alzheimer's disease: correlation with amyloid PET.
    Brain. 2017 Mar 5. doi: 10.1093.
    PubMed     Abstract available


  188. COULTHARD E, Knight M
    Refining Alzheimer's disease diagnosis with MRI.
    Brain. 2017;140:524-526.
    PubMed    


    February 2017
  189. BANERJEE G, Kim HJ, Fox Z, Jager HR, et al
    MRI-visible perivascular space location is associated with Alzheimer's disease independently of amyloid burden.
    Brain. 2017 Feb 17. doi: 10.1093.
    PubMed     Abstract available


  190. REEVES S, McLachlan E, Bertrand J, Antonio FD, et al
    Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
    Brain. 2017 Feb 4. doi: 10.1093.
    PubMed     Abstract available


  191. HUSAIN M
    Alzheimer's disease: time to focus on the brain, not just molecules.
    Brain. 2017;140.
    PubMed    


    January 2017
  192. PASSAMONTI L, Vazquez Rodriguez P, Hong YT, Allinson KS, et al
    18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.
    Brain. 2017 Jan 24. pii: aww340. doi: 10.1093.
    PubMed     Abstract available


  193. FAN Z, Brooks DJ, Okello A, Edison P, et al
    An early and late peak in microglial activation in Alzheimer's disease trajectory.
    Brain. 2017 Jan 24. pii: aww349. doi: 10.1093.
    PubMed     Abstract available


  194. HAYES JP, Logue MW, Sadeh N, Spielberg JM, et al
    Mild traumatic brain injury is associated with reduced cortical thickness in those at risk for Alzheimer's disease.
    Brain. 2017 Jan 11. pii: aww344. doi: 10.1093.
    PubMed     Abstract available


  195. PONTECORVO MJ, Devous MD Sr, Navitsky M, Lu M, et al
    Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Brain. 2017 Jan 11. pii: aww334. doi: 10.1093.
    PubMed     Abstract available


  196. CAPSONI S, Malerba F, Carucci NM, Rizzi C, et al
    The chemokine CXCL12 mediates the anti-amyloidogenic action of painless human nerve growth factor.
    Brain. 2017;140.
    PubMed     Abstract available


  197. AHMED RM, Landin-Romero R, Collet TH, van der Klaauw AA, et al
    Energy expenditure in frontotemporal dementia: a behavioural and imaging study.
    Brain. 2017;140.
    PubMed     Abstract available


    December 2016
  198. ALVES S, Churlaud G, Audrain M, Michaelsen-Preusse K, et al
    Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice.
    Brain. 2016 Dec 20. pii: aww330. doi: 10.1093.
    PubMed     Abstract available


  199. DONG A, Toledo JB, Honnorat N, Doshi J, et al
    Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers.
    Brain. 2016 Dec 20. pii: aww319. doi: 10.1093.
    PubMed     Abstract available


    October 2016
  200. ROGAEVA E, Schmitt-Ulms G
    Does BDNF Val66Met contribute to preclinical Alzheimer's disease?
    Brain. 2016;139.
    PubMed    


    September 2016
  201. JAMES BD, Wilson RS, Boyle PA, Trojanowski JQ, et al
    TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.
    Brain. 2016.
    PubMed     Abstract available


    March 2016
  202. SCHWARZ AJ, Yu P, Miller BB, Shcherbinin S, et al
    Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
    Brain. 2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: